| Table 1. Baseline and treatment characteristic in POSEIDON and NON-POSEIDON groups | ||||||||
| POSEIDON | 1a | 1b | 2a | 2b | 3 | 4 | NON-POSEIDON | |
|---|---|---|---|---|---|---|---|---|
| Cases | 54 | 1 | 10 | 7 | 10 | 8 | 18 | 358 |
| Age of female patient (*) | 36.69 (35.64-37.73) |
33.00 | 33.00 (32.33-33.67) |
39.00 (35.80-42.20) |
36.70 (35.63-37.77) |
32.13 (30.91-33.34) |
40.06 (38.81-41.30) |
34.44 (33.99-34.90) |
| Infertility duration (years) (*) | 5.14 (4.06-6.21) |
3.00 | 6.20 (2.93-9.47) |
6.71 (3.35-10.08) |
6.60 (3.54-9.66) |
3.88 (2.50-5.25) |
3.53 (1.57-5.50) |
5.13 (4.74-5.52) |
| AFC (*) | 7.75 (5.71-9.78) |
20 | 14.50 (7.37-21.63) |
5.86 (4.87-6.85) |
11.80 (7.02-16.58) |
3.50 (2.61-4.39) |
2.94 (2.48-3.41) |
13.53 (12.84-14.22) |
| GnRH analogues (a-GnRH/ant-GnRH/without) |
14/34/6 | 0/1/0 | 4/6/0 | 4/3/0 | 1/8/1 | 2/4/2 | 3/12/3 | 77/278/3 |
| Gonadotropin dose (IU) (*) | 1883.33 1647.81-2118.86) |
2400.00 | 1967.50 (1646.80-2288.20) |
2403.57 (1739.81-3067.33) |
2242.50 (1850.32-2634.68) |
2164.29 (1099.89-3228.68) |
1345.59 (890.66-1800.52) |
2121.34 (2062.49-2180.18) |
| MII oocytes (*) | 5.08 (3.86-6.30) |
14 | 9.30 (5.84-12.76) |
3.14 (0.61-5.67) |
7.10 (4.11-10..09) |
2.57 (1.39-3.75) |
2.56 (1.70-3.41) |
8.45 (7.93-8.97) |
| Day of transfer (cleavage/blastocyst) |
40/14 | 0/1 | 3/7 | 6/1 | 8/2 | 8/0 | 15/3 | 231/127 |
| Embryos transferred (*) | 2.35 (2.04-2.67) |
2.00 | 2.80 (2.24-3.36) |
2.00 (1.08-2.92) |
3.20 (2.32-4.08) |
2.25 (1.38-3.12) |
1.89 (1.38-2.40) |
2.68 (2.60-2.77) |
*95% confidence interval